FBP1 and cancer: However, these small molecule inhibitors do not act by directly targeting FBP1, and studies of their effects on FBP1 expression remain at the preclinical study stage.Therefore, it is crucial to conduct preclinical and clinical studies on these drugs in patients with low FBP1-expressing cancers and to develop new small molecule inhibitors that directly target FBP1.